Supportive care in myeloma-when treating the clone alone is not enough

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Multiple myeloma survival has improved, with T-cell-redirecting therapies showing promise.
• Treatment-related adverse events remain a challenge, impacting patient quality of life and adherence.

Purpose of the Study:

• To outline essential supportive care strategies for patients with multiple myeloma receiving T-cell-redirecting therapies.
• To address key complications including bone disease, thrombosis, on-target, off-tumor toxicities, and infections.

Main Methods:

• Review of bone disease prevention strategies.
• Description of a risk-adapted approach to thrombosis prophylaxis.
• Management guidelines for specific toxicities associated with GPRC5D-targeting therapies.
• Strategies for infectious prophylaxis during T-cell-redirecting therapies.

Main Results:

• Specific recommendations are provided for preventing bone complications.
• A tailored prophylaxis plan for thrombosis based on patient risk is detailed.
• Methods for managing on-target, off-tumor effects of GPRC5D-targeting agents are outlined.
• Prophylactic measures against infections during these advanced therapies are discussed.

Conclusions:

• Optimized supportive care is crucial for enhancing patient well-being and treatment adherence in multiple myeloma.
• Effective management of adverse events can lead to better long-term disease control and improved outcomes with T-cell-redirecting therapies.